Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$10.48 +2.2%	$10.39	$3.52 ▼ $23.40	$478.70M	0.85	1.73 million shs	994,418 shs
CTMX CytomX Therapeutics	$2.13 -4.5%	$1.03	$0.40 ▼ $2.55	$171.72M	1.11	2.13 million shs	3.74 million shs
EPIX ESSA Pharma	$1.61 -4.7%	$1.65	$1.40 ▼ $7.88	$71.47M	1.69	339,751 shs	372,214 shs
IXHL Incannex Healthcare	$0.27 +24.0%	$0.46	$0.08 ▼ $3.55	$7.95M	7.67	11.10 million shs	201.95 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	+2.24%	-4.81%	-19.57%	-27.52%	+74.96%
CTMX CytomX Therapeutics	-4.48%	+3.40%	+200.00%	+212.68%	+21.71%
EPIX ESSA Pharma	-4.73%	-2.42%	-9.04%	-5.29%	-74.80%
IXHL Incannex Healthcare	+24.02%	+12.50%	-53.53%	-79.85%	-90.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CAPR Capricor Therapeutics	1.8159 of 5 stars	3.5	2.0	0.0	2.0	0.8	0.6
CTMX CytomX Therapeutics	4.2545 of 5 stars	3.5	1.0	4.7	3.1	2.5	1.3
EPIX ESSA Pharma	1.9438 of 5 stars	2.0	3.0	0.0	3.1	2.5	1.3
IXHL Incannex Healthcare	0.424 of 5 stars	0.0	2.0	0.0	3.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	3.00	Buy	$35.50	238.74% Upside
CTMX CytomX Therapeutics	3.00	Buy	$5.33	150.39% Upside
EPIX ESSA Pharma	2.00	Hold	$2.00	24.22% Upside
IXHL Incannex Healthcare	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CAPR, EPIX, CTMX, and IXHL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CAPR Capricor Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$31.00
5/15/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$2.50 ➝ $5.00
5/15/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $5.00
5/14/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
5/12/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00 ➝ $6.00
4/14/2025	CTMX CytomX Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$3.25 ➝ $2.50
3/20/2025	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$30.00 ➝ $30.00
3/17/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $77.00
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/4/2025	CAPR Capricor Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$77.00 ➝ $77.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$17.36M	27.57	N/A	N/A	$0.73 per share	14.36
CTMX CytomX Therapeutics	$147.56M	1.16	N/A	N/A	($0.71) per share	-3.00
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.68 per share	N/A
IXHL Incannex Healthcare	$98K	81.09	N/A	N/A	$0.05 per share	5.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$22.29M	-$1.42	N/A	N/A	N/A	-146.86%	-112.95%	-57.00%	8/6/2025 (Estimated)
CTMX CytomX Therapeutics	-$570K	$0.48	12.53	N/A	N/A	10.96%	-41.47%	8.11%	8/14/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-24.61%	-23.87%	8/4/2025 (Estimated)
IXHL Incannex Healthcare	-$18.46M	-$1.21	N/A	∞	N/A	N/A	-289.30%	-154.96%	N/A

Latest CAPR, EPIX, CTMX, and IXHL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q3 2025	IXHL Incannex Healthcare	-$0.46	-$0.24	+$0.22	-$0.20	$0.16 million	$0.10 million
5/13/2025	Q1 2025	CAPR Capricor Therapeutics	-$0.33	-$0.53	-$0.20	-$0.53	$3.16 million	$2.73 million
5/12/2025	Q1 2025	CTMX CytomX Therapeutics	$0.18	$0.27	+$0.09	$0.27	$35.42 million	$50.92 million
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A
3/19/2025	Q4 2024	CAPR Capricor Therapeutics	-$0.31	-$0.16	+$0.15	-$0.16	$9.87 million	$11.13 million
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	4.19	4.19
CTMX CytomX Therapeutics	N/A	1.04	1.04
EPIX ESSA Pharma	N/A	33.12	33.12
IXHL Incannex Healthcare	2.47	1.80	1.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
CTMX CytomX Therapeutics	67.77%
EPIX ESSA Pharma	75.12%
IXHL Incannex Healthcare	0.43%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	10.50%
CTMX CytomX Therapeutics	7.00%
EPIX ESSA Pharma	15.50%
IXHL Incannex Healthcare	26.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	N/A	45.68 million	40.01 million	Optionable
CTMX CytomX Therapeutics	170	80.62 million	72.78 million	Optionable
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
IXHL Incannex Healthcare	3	29.43 million	13.12 million	Not Optionable

CAPR, EPIX, CTMX, and IXHL Headlines

Recent News About These Companies

Cannabis Stocks To Follow Today - May 19th

May 22, 2025 | americanbankingnews.com

Top Cannabis Stocks To Follow Now - May 20th

May 22, 2025 | americanbankingnews.com

Incannex Healthcare boosts share offering capacity

May 21, 2025 | uk.investing.com

Incannex Cancels Warrants to Strengthen Shareholder Position

May 20, 2025 | tipranks.com

Incannex Healthcare Inc. Completes $16.7 Million Capital Raise to Reduce Potential Shareholder Dilution

May 20, 2025 | quiverquant.com

Incannex Healthcare Expands Share Issuance Agreement

May 20, 2025 | tipranks.com

Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution

May 20, 2025 | globenewswire.com

Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants

May 16, 2025 | globenewswire.com

Incannex Healthcare Adjusts Series A Warrants Agreement

May 15, 2025 | tipranks.com

Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates

May 15, 2025 | globenewswire.com

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily ...

May 14, 2025 | gurufocus.com

Incannex Completes Patient Dosing in Phase 2 Study

May 14, 2025 | tipranks.com

Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

May 14, 2025 | globenewswire.com

Incannex enters agreement for potential stock sales

April 9, 2025 | investing.com

Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)

April 3, 2025 | globenewswire.com

Incannex Healthcare Stock Price, Quotes and Forecasts | NASDAQ:IXHL | Benzinga

March 9, 2025 | benzinga.com

Incannex Healthcare Inc. Announces Pricing of $12. ...

March 7, 2025 | gurufocus.com

Incannex Healthcare Inc. Announces $12.5 Million Offering of Common Stock and Series A Warrants

March 7, 2025 | quiverquant.com

Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules

March 7, 2025 | globenewswire.com

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025

February 18, 2025 | newsfilecorp.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAPR, EPIX, CTMX, and IXHL Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$10.48 +0.23 (+2.24%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$10.52 +0.04 (+0.43%)

As of 05/27/2025 07:56 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

CytomX Therapeutics NASDAQ:CTMX

$2.13 -0.10 (-4.48%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$2.13 +0.00 (+0.23%)

As of 05/27/2025 07:55 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

ESSA Pharma NASDAQ:EPIX

$1.61 -0.08 (-4.73%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$1.67 +0.06 (+3.73%)

As of 05/27/2025 05:41 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Incannex Healthcare NASDAQ:IXHL

$0.27 +0.05 (+24.02%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$0.25 -0.02 (-7.41%)

As of 05/27/2025 07:59 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time